

Our Laval, Canada Facility

**MARIE-CHRISTINE LOCAS**

Site Head

We work with the Bill & Melinda Gates Foundation, CEPI U.K. Vaccine Task Force, and BARDA referral lab.

We maintain strategic partnerships with United Kingdom Health Security Agency (UKHSA), Porton Down, U.K.

Key abilities

We house a broad expertise in various disease areas

- Respiratory
 - » Influenza, RSV, *N. meningitidis*, *S. pneumonia*, *B. pertussis*, *C. diphtheriae*, rhinovirus, coronavirus
- Enteric
 - » *E. coli*, *Shigella sp.*, *C. difficile*, rotavirus, *Salmonella sp.*
- Zoonotic
 - » Chikungunya, Zika, Dengue, malaria, Nipah, yellow fever
- Sexually transmitted
 - » CMV, HSV, HBV, HCV, EBV
- Others
 - » HPV, adenovirus, AAV, CoxV, measles, mumps, rubella, varicella zoster, tetanus, *S. aureus*, LCMV, GBS, LCMV, polio, vaccinia

Laboratory

- 75,000-square-foot, state-of-the-art BSL2 laboratories and offices in our main building at 525 Blvd. Cartier West
- >1 MM tube storage (-20°C, -80°C, and LN2)
- 1,500-square-foot BSL3 new laboratory including animal facility opening Q4 2023 at Institut Armand Frappier
- High-throughput clinical testing with a capacity of 500,000 samples per year
- Various immunology *in vivo* models including rodents, canines, and nonhuman primates



Notable certifications:
GCLP accreditation and
R&D, in vivo: AALAC, CCAC,
and OLAW

Lab equipment and techniques

- AKTA Exporer, Avant 25
- SpectraMax 5Me
- QuantStudio 7
- ForteBio Octet Red96
- Luminex X200, FlexMap
- MSD S600
- Fortessa X20
- CTL S6 Ultimate
- SpectraMax ID3
- VersaMax Envision
- Integra Systems Assist Plus, ViaFlow and ViaFill
- Vi-Cell XR
- BioTek Cytation 7
- InDevR CypherOne



About our Vaccine services

With unrivaled expertise in immunology, four operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, IQVIA Laboratories is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic, and oncologic fields. Our versatile team of scientists, working with state-of-the-art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.